title: Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with congenital factor XI deficiency.
abstract: We report our experience with the use of recombinant activated factor VII (rFVIIa) during cardiac surgery in a 4.5-year-old boy with severe congenital FXI deficiency and a congenital heart disease. After weaning the patient from cardiopulmonary bypass, the first intravenous dose of rFVIIa (90 microg/kg) was administered. This same dosage was repeated eight more times, at 2- to 4-hour intervals postoperatively. There was no bleeding during and after surgery. rFVIIa treatment may be used successfully in children with severe FXI deficiency in major operations such as open heart surgery.
authors: Department of Pediatric Hematology, Baskent University Faculty of Medicine, 6. Cadde, No: 72/3, 06490 Bahcelievler, Ankara, Turkey. zekaiavci@yahoo.com
authors: Zekai
authors: Z
authors: Avci
authors: Baris
authors: B
authors: Malbora
authors: Mahmut
authors: M
authors: Gokdemir
authors: Suleyman
authors: S
authors: Ozkan
authors: Namik
authors: N
authors: Ozbek
mesh_terms: D000015:Abnormalities, Multiple / Q000601:surgery*; D002315:Cardiopulmonary Bypass; D002675:Child, Preschool; D015942:Factor VIIa / Q000008:administration & dosage / Q000627:therapeutic use*; D005173:Factor XI Deficiency / Q000151:congenital* / Q000188:drug therapy*; D006330:Heart Defects, Congenital / Q000601:surgery*; D006801:Humans; D008297:Male; D008943:Mitral Valve / Q000601:surgery; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D011994:Recombinant Proteins; C103587:recombinant FVIIa; D015942:Factor VIIa